Drug Information

Drug General Information
Drug ID
D05VTN
Former ID
DIB013367
Drug Name
CCX-354
Synonyms
CCX-354-C; CCR1 antagonist (rheumatoid arthritis), ChemoCentryx/GlaxoSmithKline; CCR1 antagonists (autoimmune diseases), Forest Laboratories/ChemoCentryx
Indication Autoimmune diabetes [ICD10:E08-E13] Phase 2 [523255]
Company
ChemoCentryx Inc
Structure
Download
2D MOL

3D MOL
Canonical SMILES
C(=O)(Cn1c2c(cccn2)c(n1)c1ncc[nH]1)N1CCN(CC1)c1cc(c(cc1<br />)Cl)OC
Target and Pathway
Target(s) C-C chemokine receptor type 1 Target Info Antagonist [531908]
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
NetPath Pathway IL5 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
TNFalpha Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Reactome Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 523255ClinicalTrials.gov (NCT01242917) A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy. U.S. National Institutes of Health.
Ref 531908Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.